Company intelligence / Profile preview
Valerion Therapeutics
Concord, Massachusetts, United Statesvalerion.com ↗
- Ownership
- Private
- Employees
- ~1
- Development stage
- Other
01
Overview
The company developed a proprietary cell-penetrating antibody (3E10) to target the cytoplasm of affected tissues, particularly for orphan genetic diseases. Their platform enabled enhanced intracellular delivery of active therapeutic molecules.
- Therapeutic areas
- Rare DiseasesNeurologyMetabolic Disorders
- Modalities
- Antibody-mediated delivery platformprotein therapeuticsenzyme therapeuticsmacromolecule delivery
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Valerion Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Valerion Therapeutics.